Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Emerging Treatments
100%
Metastatic Triple-negative Breast Cancer
100%
Overall Survival
66%
Breast Cancer Patients
66%
New Agents
33%
Heavily Pretreated
33%
Breast Cancer Susceptibility Gene 1 (BRCA1)
33%
Mutation Carriers
33%
Palliation
33%
Treatment Goals
33%
Taxanes
33%
Antibody-drug Conjugate
33%
Anthracyclines
33%
Sequential Chemotherapy
33%
PD-L1 Expression
33%
Nab-paclitaxel
33%
Germline BRCA
33%
Atezolizumab
33%
Sacituzumab Govitecan
33%
Poly(adenosine diphosphate-ribose) Polymerase inhibitor
33%
IMMU-132
33%
Medicine and Dentistry
Emerging Treatment
100%
Triple Negative Breast Cancer
100%
Overall Survival
66%
Symptomatic Treatment
33%
Germ Cell
33%
Paclitaxel
33%
Poly ADP Ribose Polymerase
33%
Anthracycline
33%
Programmed Death-Ligand 1
33%
Antibody-Drug Conjugate
33%
Atezolizumab
33%
3 (2 Diisopropylaminoethylamino) 2',6' Dimethylpropionanilide
33%
Sacituzumab Govitecan
33%
Nursing and Health Professions
Triple Negative Breast Cancer
100%
Overall Survival
66%
Palliative Therapy
33%
Food and Drug Administration
33%
Anthracycline
33%
Paclitaxel
33%
3 (2 Diisopropylaminoethylamino) 2',6' Dimethylpropionanilide
33%
Atezolizumab
33%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase
33%
Sacituzumab Govitecan
33%
Antibody Drug Conjugate
33%
Pharmacology, Toxicology and Pharmaceutical Science
Triple Negative Breast Cancer
100%
Overall Survival
66%
Chemotherapy
33%
Paclitaxel
33%
Taxane
33%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase
33%
Anthracycline
33%
Antibody Drug Conjugate
33%
Atezolizumab
33%
Sacituzumab Govitecan
33%
3 (2 Diisopropylaminoethylamino) 2',6' Dimethylpropionanilide
33%